Nkarta focuses on the development of natural killer (NK) cell therapies for the treatment of cancer and autoimmune diseases, utilizing proprietary technology for NK cell expansion.

Nkarta, Inc.

Nkarta, Inc., a a clinical-stage biopharmaceutical company, develops and commercializes cell therapies for cancer treatment. The company's approach for cellular immunotherapy involves chimeric antigen receptors on the surface of a natural killer (NK) cell that enable the cell to recognize specific proteins or antigens that are present on the surface of tumor cells. Its two co-lead product candidates are NKX101, which is in Phase I clinical trials for the treatment of relapsed/refractory acute myeloid leukemia or higher risk myelodysplastic syndromes; and NKX019, a pre-clinical product, which is based on the ability to treat various B cell malignancies by targeting the CD19 antigen found on these types of cancerous cells. The company has a research collaboration agreement with CRISPR Therapeutics AG. Nkarta, Inc. was incorporated in 2015 and is based in South San Francisco, California.

news_impact_assignment_basic

key_people

merger_acquisitions

network_dossier

public_peers

news_daily_refresh

news_processing_daily_refresh

news_impact_assignment_daily

news_processing_basic

legal

legal_dossier

bundesanzeiger

events_dossier

partnerships_market_presence_dossier

partnerships_market_presence

company_dossier

network

strategic_challenges

industry_trends

strategic_challenges_dossier

industry_trends_dossier

company_summary

events

network_mapping

transactions_dossier

swot_dossier

signals

financial_statements

crunchbase_trigger

crunchbase_profile

li_profile

financials_download_nd

private_financials

swot_analysis

financial_legal_advisories

company_structure

industry_analysis

financial_analysis

funding_rounds_analysis

regulatory_analysis

competition_analysis

news_impact_assignment_advanced

news_processing_advanced

news_advanced

purchaser_profile

network_onboarding

translate_crunchbase_fundingrounds

peers

customer_profile

news_basic

valuation

news impact assignment basic	general
public peers	general	Nov 12, 2024 7:26 AM	05349729
news daily refresh	general
news processing daily refresh	general
news impact assignment daily	general
news processing basic	general
company summary	general
signals	general	Nov 12, 2024 7:26 AM	aa91b36d
crunchbase trigger	general	Nov 27, 2024 12:50 PM	a0488019
crunchbase profile	general
li profile	general	Nov 12, 2024 7:26 AM	dd41737c
translate crunchbase fundingrounds	general
peers	general	Nov 12, 2024 7:26 AM	62fe5356
news basic	general	Nov 12, 2024 7:26 AM	c9838f0e
bundesanzeiger	filings
financials download nd	financials
private financials	financials

COM:NKARTATX

Nkarta, Inc.

Last Close

2.44

22/11 21:00

Market Cap

386.16M

Beta: -

Volume Today

1.94M

Avg: -